Trials / Active Not Recruiting
Active Not RecruitingNCT06223958
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 344 (actual)
- Sponsor
- Ocular Therapeutix, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTX-TKI (axitinib implant) | Intravitreal Injection of OTX-TKI (axitinib implant) |
| DRUG | Aflibercept | Injection of 2mg (0.05mL) of aflibercept |
Timeline
- Start date
- 2024-01-29
- Primary completion
- 2026-04-29
- Completion
- 2027-09-27
- First posted
- 2024-01-25
- Last updated
- 2025-04-18
Locations
108 sites across 3 countries: United States, Argentina, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06223958. Inclusion in this directory is not an endorsement.